AbbVie Inc. Average Days of Payables

Average Days of Payables of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Days of Payables growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Average Days of Payables for 2019 was 0.0 (a -100.0% decrease from previous year)
  • Annual Average Days of Payables for 2018 was 564.24 (a 6.45% increase from previous year)
  • Annual Average Days of Payables for 2017 was 530.03 (a -9.7% decrease from previous year)
  • Twelve month Average Days of Payables ending December 30, 2019 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Twelve month trailing Average Days of Payables decreased by -100.0% year-over-year
Trailing Average Days of Payables for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
0.0 598.15 559.63 576.69
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Days of Payables of AbbVie Inc.

Most recent Average Days of Payablesof ABBV including historical data for past 10 years.

Interactive Chart of Average Days of Payables of AbbVie Inc.

AbbVie Inc. Average Days of Payables for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 0.0
2018 564.24
2017 530.03
2016 586.99
2015 686.44
2014 573.48
2013 513.76
2012 464.27
2011 462.72
2010 30.33
2009 0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.